{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T10:38:09Z","timestamp":1781865489556,"version":"3.54.5"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.clml.2020.10.015","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T23:50:09Z","timestamp":1604101809000},"page":"73-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic Advances"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1153-2294","authenticated-orcid":false,"given":"Dai","family":"Chihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieron","family":"Dunleavy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.10.015_bib1","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.clml.2020.10.015_bib2","doi-asserted-by":"crossref","first-page":"28897","DOI":"10.18632\/oncotarget.25622","article-title":"Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis","volume":"9","author":"Chihara","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2020.10.015_bib3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bjh.14073","article-title":"Trends in primary central nervous system lymphoma incidence and survival in the US","volume":"174","author":"Shiels","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.10.015_bib4","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","article-title":"Primary CNS lymphoma","volume":"35","author":"Grommes","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.10.015_bib5","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/neuonc\/nox187","article-title":"The elderly left behind\u2014changes in survival trends of primary central nervous system lymphoma over the past four decades","volume":"20","author":"Mendez","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.clml.2020.10.015_bib6","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","article-title":"Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10","volume":"20","author":"DeAngelis","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.10.015_bib7","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2020.10.015_bib8","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"Rubenstein","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.10.015_bib9","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","article-title":"R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma","volume":"125","author":"Omuro","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.10.015_bib10","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2020.10.015_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","volume":"117","author":"Soussain","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2020.10.015_bib12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdz032","volume":"30","author":"Ghesquieres","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.10.015_bib13","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood-2018-02-835496","article-title":"Phase 1 study of pomalidomide and dexamethasone for relapsed\/refractory primary CNS or vitreoretinal lymphoma","volume":"132","author":"Tun","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.10.015_bib14","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1200\/JCO.2015.64.9897","article-title":"Phase II trial of temsirolimus for relapsed\/refractory primary CNS lymphoma","volume":"34","author":"Korfel","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.10.015_bib16","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.1985.3.4.490","article-title":"Primary lymphomas of the central nervous system: patterns of failure and factors that influence survival","volume":"3","author":"Loeffler","year":"1985","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.10.015_bib17","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1200\/JCO.1992.10.4.635","article-title":"Combined modality therapy for primary CNS lymphoma","volume":"10","author":"DeAngelis","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.10.015_bib18","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1200\/JCO.2003.03.108","article-title":"High-dose methotrexate\u2013based chemotherapy followed by consolidating radiotherapy in non\u2013AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group phase II trial 20962","volume":"21","author":"Poortmans","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.10.015_bib19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000055310","article-title":"Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients","volume":"60","author":"Ferreri","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.clml.2020.10.015_bib20","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/JCO.2000.18.3.519","article-title":"Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma","volume":"18","author":"O\u2019Brien","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.10.015_bib21","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2006.06.6910","article-title":"Long-term follow-up of high-dose methotrexate\u2013based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma","volume":"24","author":"Gavrilovic","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.10.015_bib22","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1200\/JCO.2015.64.8634","article-title":"Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG Oncology RTOG 0227","volume":"34","author":"Glass","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.10.015_bib23","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2007.12.5062","article-title":"Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma","volume":"25","author":"Shah","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.10.015_bib24","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2020.10.015_bib25","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","article-title":"Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model","volume":"24","author":"Abrey","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.10.015_bib26","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.bbmt.2014.01.025","article-title":"High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed\/refractory diffuse large B cell lymphoma: a nationwide retrospective study","volume":"20","author":"Chihara","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.10.015_bib27","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.10.015_bib28","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1158\/1078-0432.CCR-14-2116","article-title":"Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas","volume":"21","author":"Braggio","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.10.015_bib29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ctrv.2018.01.002","article-title":"Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma","volume":"65","author":"Dunleavy","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clml.2020.10.015_bib30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.clml.2020.10.015_bib31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/nan.12259","article-title":"Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas","volume":"42","author":"Nakamura","year":"2016","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.clml.2020.10.015_bib32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell\u2013receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.clml.2020.10.015_bib33","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2020.10.015_bib34","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2020.10.015_bib35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1212\/WNL.0000000000003420","article-title":"Ibrutinib monotherapy in relapsed\/refractory CNS lymphoma: a retrospective case series","volume":"88","author":"Chamoun","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.clml.2020.10.015_bib36","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1073\/pnas.1311846111","article-title":"High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell\u2013like diffuse large B-cell lymphoma cells","volume":"111","author":"Mathews Griner","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2020.10.015_bib37","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","article-title":"Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma","volume":"133","author":"Grommes","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.10.015_bib38","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00262-008-0512-7","article-title":"Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation","volume":"57","author":"Zhu","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clml.2020.10.015_bib39","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2020.10.015_bib40","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.clml.2020.10.015_bib41","doi-asserted-by":"crossref","first-page":"22382","DOI":"10.1074\/jbc.M100938200","article-title":"Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity","volume":"276","author":"Keifer","year":"2001","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2020.10.015_bib42","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1002\/cncr.26135","article-title":"Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell\u2013like than in germinal center B-cell\u2013like phenotype","volume":"117","author":"Hernandez-Ilizaliturri","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.10.015_bib43","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1212\/WNL.0000000000001158","article-title":"Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma","volume":"84","author":"Houillier","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.clml.2020.10.015_bib44","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/bloodadvances.2017014845","article-title":"Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma","volume":"2","author":"Rubenstein","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2020.10.015_bib45","doi-asserted-by":"crossref","first-page":"e71754","DOI":"10.1371\/journal.pone.0071754","article-title":"Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2020.10.015_bib46","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1073\/pnas.1008969108","article-title":"Critical role of PI3K signaling for NF-kappaB\u2013dependent survival in a subset of activated B-cell\u2013like diffuse large B-cell lymphoma cells","volume":"108","author":"Kloo","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2020.10.015_bib47","doi-asserted-by":"crossref","first-page":"vi106","DOI":"10.1093\/annonc\/mdw367.13","article-title":"Phase II study of single agent buparlisib in recurrent\/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)","volume":"27","author":"Grommes","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.10.015_bib48","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1182\/blood-2019-126214","article-title":"Phase Ib of copanlisib in combination with ibrutinib in recurrent\/refractory primary CNS lymphoma (PCNSL)","volume":"134","author":"Grommes","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.10.015_bib49","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.10.015_bib50","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.10.015_bib51","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.10.015_bib52","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.10.015_bib53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.10.015_bib54","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2019004162","article-title":"Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma","author":"Neelapu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.10.015_bib55","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.10.015_bib56","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMc1704610","article-title":"Anti-CD19 CAR T cells in CNS diffuse large\u2013B-cell lymphoma","volume":"377","author":"Abramson","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.10.015_bib57","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020305826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020305826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:36:09Z","timestamp":1761870969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020305826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S2152265020305826"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.10.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic Advances","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}